Follow Humana to never miss an important update.
Barclays upgraded the health insurer to its top rating, Overweight, and set a price target of $515. This is well above the current average analyst target of $424 and suggests the firm sees significant room for the stock to rise from its current price of about $401.
The move comes as Humana works through a year of lower profits to sign up more members in its Medicare Advantage plans, which are private health insurance options for seniors. While this growth is expensive today, the upgrade reflects a view that the company is successfully building a much larger business that will be far more profitable once costs stabilize in the coming years.
Source: Barclays
The board approved a cash payment of about 89 cents per share for the current quarter. This is a routine move that keeps the payout at the same level as the previous quarter. For a long-term owner, this confirms that the company's cash position remains steady enough to continue its regular return to shareholders while it works through a period of higher medical costs.
Source: Business Wire
A wave of summer earnings reports from across the sector suggests that the high medical costs that have squeezed profits for a year are finally coming under control. This is a vital sign for Humana, which has been sacrificing its own profit margins to sign up more members in its Medicare Advantage plans for seniors.
For our view to work, these internal costs for member care must stabilize so that insurance margins can return to their historical targets of 4 to 5 percent. If costs are indeed leveling off across the industry, it makes it much more likely that Humana can turn its massive new membership base into a larger source of earnings by 2027.
Source: Forbes
Wolfe Research set a target of $450 for the stock, which is higher than the average analyst target of $419. While a target is just an estimate of where the price might go, this move reflects a growing expectation that the company can recover its earnings power as it works through a temporary dip in government bonus payments.
Source: Wolfe Research
Humana has named Dr. Shantanu Nundy as its new Chief Medical Officer, starting August 31. Dr. Nundy is a physician and executive who has focused on using technology to simplify how patients receive care. At Humana, he will lead the clinical side of the business and help design its digital platforms and artificial intelligence tools.
This hire matters because Humana is trying to lower its medical costs by managing patient health more efficiently. Better technology and AI can help the company spot health issues earlier or handle claims with less waste. If Dr. Nundy can make these systems more effective, it would help Humana return to its target profit margins over the next few years.
Source: Business Wire
Management has a perfect record of clearing its own bars for two years straight. These consistent beats suggest they have a firm grip on their costs even while the business grows rapidly.
| Expectation | |
|---|---|
| EPS | $-1.04 |
| Revenue | $40.87B |